Alexion Pharmaceuticals Inc.

163.68+6.14+3.90%Vol 7.29M1Y Perf 65.99%
Apr 16th, 2021 16:00 DELAYED
BID163.64 ASK163.68
Open164.05 Previous Close157.54
Pre-Market- After-Market163.68
 - -  - -%
Target Price
162.25 
Analyst Rating
Moderate Buy 1.78
Potential %
-0.87 
Finscreener Ranking
★★★+     51.69
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★+     49.11
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★+     63.36
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap36.16B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
98.68 
Earnings Date
5th May 2021

Today's Price Range

163.54164.60

52W Range

94.82164.60

5 Year PE Ratio Range

6.80429.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
5.59%
1 Month
6.82%
3 Months
4.45%
6 Months
31.86%
1 Year
65.99%
3 Years
44.49%
5 Years
6.92%
10 Years
223.19%

TickerPriceChg.Chg.%
ALXN163.686.14003.90
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
2.70
3.60
0.18
0.24
6.40
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
90.90
11.10
16.50
24.10
-0.32
RevenueValueIndustryS&P 500US Markets
4.63B
21.04
19.08
17.48
Earnings HistoryEstimateReportedSurprise %
Q04 20202.252.7220.89
Q03 20202.343.0731.20
Q02 20202.322.8723.71
Q01 20202.443.0223.77
Q04 20192.372.515.91
Q03 20192.272.5512.33
Q02 20192.132.4615.49
Q01 20191.992.1910.05
Earnings Per EndEstimateRevision %Trend
3/2021 QR3.118.36Positive
6/2021 QR2.94-2.65Negative
12/2021 FY11.760.26Positive
12/2022 FY13.30--
Next Report Date5th May 2021
Estimated EPS Next Report3.11
Estimates Count6
EPS Growth Next 5 Years %16.00
Volume Overview
Volume7.29M
Shares Outstanding220.91M
Trades Count60.47K
Dollar Volume336.13M
Avg. Volume2.68M
Avg. Weekly Volume2.89M
Avg. Monthly Volume2.13M
Avg. Quarterly Volume2.59M

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) stock closed at 163.68 per share at the end of the most recent trading day (a 3.9% change compared to the prior day closing price) with a volume of 7.31M shares and market capitalization of 36.16B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3837 people. Alexion Pharmaceuticals Inc. CEO is Ludwig N. Hantson.

The one-year performance of Alexion Pharmaceuticals Inc. stock is 65.99%, while year-to-date (YTD) performance is 4.76%. ALXN stock has a five-year performance of 6.92%. Its 52-week range is between 94.82 and 164.6, which gives ALXN stock a 52-week price range ratio of 98.68%

Alexion Pharmaceuticals Inc. currently has a PE ratio of 57.20, a price-to-book (PB) ratio of 2.91, a price-to-sale (PS) ratio of 7.32, a price to cashflow ratio of 11.40, a PEG ratio of 2.32, a ROA of 3.24%, a ROC of 7.65% and a ROE of 5.04%. The company’s profit margin is -0.32%, its EBITDA margin is 16.50%, and its revenue ttm is $4.63 Billion , which makes it $21.04 revenue per share.

Of the last four earnings reports from Alexion Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.11 for the next earnings report. Alexion Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Alexion Pharmaceuticals Inc. is Moderate Buy (1.78), with a target price of $162.25, which is -0.87% compared to the current price. The earnings rating for Alexion Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alexion Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alexion Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.32, ATR14 : 3.16, CCI20 : 410.65, Chaikin Money Flow : -0.14, MACD : 0.76, Money Flow Index : 64.33, ROC : 6.67, RSI : 68.00, STOCH (14,3) : 92.84, STOCH RSI : 1.00, UO : 64.50, Williams %R : -7.16), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alexion Pharmaceuticals Inc. in the last 12-months were: Daniel A. Bazarko (Sold 0 shares of value $-2 816 740 ), Daniel A. Bazarko (Sold 24 066 shares of value $3 795 233 ), Indrani Lall Franchini (Sold 6 853 shares of value $785 981 ), Tanisha Carino (Sold 1 530 shares of value $187 058 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (55.56 %)
11 (57.89 %)
12 (66.67 %)
Moderate Buy
2 (11.11 %)
2 (10.53 %)
2 (11.11 %)
Hold
6 (33.33 %)
6 (31.58 %)
4 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.78
Moderate Buy
1.74
Moderate Buy
1.56

Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

CEO: Ludwig N. Hantson

Telephone: +1 475-230-2596

Address: 121 Seaport Boulevard, Boston 02210, MA, US

Number of employees: 3 837

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

66%34%

Bearish Bullish

59%41%

Bearish Bullish

57%43%

News

Stocktwits